Eravacycline: A Review in Complicated Intra-Abdominal Infections

[1]  J. Solomkin,et al.  IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  L. Tsai,et al.  1978. Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection , 2018, Open Forum Infectious Diseases.

[3]  E. Efimova,et al.  1976. Pooled Analysis of Safety Data From Phases 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections , 2018, Open Forum Infectious Diseases.

[4]  Jian Zhou,et al.  Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline , 2018, Antimicrobial Agents and Chemotherapy.

[5]  D. Nicolau,et al.  Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. , 2018, International journal of antimicrobial agents.

[6]  D. Snydman,et al.  Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates , 2018, Antimicrobial Agents and Chemotherapy.

[7]  J. Karlowsky,et al.  In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. , 2017, Diagnostic microbiology and infectious disease.

[8]  P. Higgins,et al.  In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. , 2018, International journal of antimicrobial agents.

[9]  S. Redican,et al.  Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects , 2017, Open Forum Infectious Diseases.

[10]  R. Bonomo,et al.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  Ionut Negoi,et al.  The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections , 2017, World Journal of Emergency Surgery.

[12]  D. Andes,et al.  In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model , 2017, Antimicrobial Agents and Chemotherapy.

[13]  J. Solomkin,et al.  Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial , 2016, JAMA surgery.

[14]  M. Rosengart,et al.  The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. , 2017, Surgical infections.

[15]  I. Morrissey,et al.  In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013–2015) , 2016 .

[16]  I. Morrissey,et al.  In Vitro Global Surveillance of Eravacycline and Comparators against Staphylococcus spp. and Enterococcus spp. Over a Three-year Period (2013-15) , 2016 .

[17]  P. Nordmann,et al.  Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1 , 2016, Antimicrobial Agents and Chemotherapy.

[18]  M. Boermeester,et al.  Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) , 2016, World Journal of Emergency Surgery.

[19]  Y. Hamada,et al.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms , 2016, Antimicrobial Agents and Chemotherapy.

[20]  N. Woodford,et al.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[21]  J. Karlowsky,et al.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent , 2016, Drugs.

[22]  A. Pantosti,et al.  Antimicrobial resistance: a global multifaceted phenomenon , 2015, Pathogens and global health.

[23]  Ventola Cl,et al.  The antibiotic resistance crisis: part 2: management strategies and new agents. , 2015, P & T : a peer-reviewed journal for formulary management.

[24]  T. Grossman,et al.  Eravacycline (TP-434) Is Efficacious in Animal Models of Infection , 2015, Antimicrobial Agents and Chemotherapy.

[25]  D. Landman,et al.  Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City , 2014, Antimicrobial Agents and Chemotherapy.

[26]  Daniel N. Wilson,et al.  Tetracycline antibiotics and resistance mechanisms , 2014, Biological chemistry.

[27]  H. Giamarellou,et al.  Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches , 2014, Expert opinion on pharmacotherapy.

[28]  J. Solomkin,et al.  Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections , 2013, Antimicrobial Agents and Chemotherapy.

[29]  T. Grossman,et al.  Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens , 2013, Antimicrobial Agents and Chemotherapy.

[30]  Daniel N. Wilson,et al.  Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic , 2012, Antimicrobial Agents and Chemotherapy.

[31]  M. Rönn,et al.  Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. , 2012, Journal of medicinal chemistry.

[32]  M. Rönn,et al.  Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. , 2012, Journal of medicinal chemistry.